Lactobacillus strain, composition and use thereof for treating syndromes and related complications of autoimmune diseases

A method of treating a cardiac or hepatic disease caused by systemic lupus erythematosus in an individual, comprising orally administering a lactic acid bacteria (LAB)-containing composition to the individual, wherein the LAB-containing composition comprises an effective amount of a LAB strain and a pharmaceutically acceptable carrier, the effective amount is 1×109 CFU/g per individual for at least 12 weeks, the individual is a mouse, and the LAB strain is Lactobacillus reuteri strain GMNL-89, CCTCC M 207154, for reducing gap junctions between cardiac cells or inhibiting activities of matrix metallopeptidase 9 (MMP-9), C-reactive protein (CRP), interleukin-1β(IL-1β), IL-6, inducible NO synthase (iNOS) and caspase-3 of a hepatocyte.